Resolution of daytime urinary incontinence · children aged 6 to 12 years with overactive bladder with urge incontinence
It is very uncertain whether voiding education with uroflowmetry and feedback changes resolution of daytime urinary incontinence at 12 months after 6… compared with anticholinergics (very low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 6 to 12 years with overactive bladder with urge incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective measurement of volume of incontinent episodes · children aged 6 to 12 years with overactive bladder with urge incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 6 to 12 years with overactive bladder with urge incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 6 to 12 years with overactive bladder with urge incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 6 to 12 years with overactive bladder with urge incontinence
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension grade ≥ 3 · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Chemotherapy with TKI followed by TKI maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · newly‐diagnosed EOC
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · newly‐diagnosed EOC
1 finding from 1 review
All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review